Royalty Pharma Offers to Acquire Elan Corp. for $11 a Share

Royalty Pharma Offers to Acquire Elan Corp. for $11 a Share

Biogen Inc. via Bloomberg

There are “substantial” risks to Elan’s plan to make acquisitions with the $3.25 billion it will receive from selling its stake in the Tysabri multiple-sclerosis medicine to Biogen Idec Inc., RP said in a statement today.